Autologous hematopoietic stem cell transplantation (HSCT) is a potentially curative therapeutic approach for various malignant hematologic and lymphoid diseases. Hematopoietic stem cells (HSCs) may be collected from the blood or the bone marrow. HSCs are capable of self-renewal and give rise to progenitor cells, multipotent cells that differentiate and proliferate into the mature cells of the b...

Objective: To assess and correlate overall quality of life the cognitive function adult patients with hematologic cancer subjected to autologous allogeneic hematopoietic stem cell transplantations up three years after treatment. Materials method: A longitudinal, observational, analytical study was conducted 55 in a reference hospital Latin America, from September 2013 February 2019, Quality Lif...

Hematopoietic stem cell transplantation (HSCT) has become an effective therapeutic option for the treatment of severe cases of autoimmune diseases (AD). Hematopoietic stem cells (HSC) can be collected from the patient (autologous), identical twin (syngenic) or HLA identical donor (allogenous). In allogenous transplantation autoagressive immunological effector cells are substituted with non-auto...

Efforts to reduce relapse of non-Hodgkin lymphoma after autologous transplantation have included ex vivo stem cell selection and/or peritransplantation immunotherapy. The late infectious and immunologic consequences of these maneuvers are not well understood, although an increase in early cytomegaloviral disease after CD34(+) stem cell selection and an alteration in immunoglobulin and T-cell re...

BACKGROUND Allogeneic and autologous haematopoietic stem cell transplantation are established treatment options for haematological malignancies and may possibly be employed to treat a range of genetic and autoimmune diseases. CASE PRESENTATION We report two patients who developed an acute myelitis within their thoracic spinal cord after allogeneic stem cell transplantation. Myelitis in these ...

Acknowledgments: preparation of this manuscript was supported by grants from Dompé Biotec SpA and Amgen Italia SpA, Milan, Italy. Received January 11, 1996; accepted June 4, 1996. T he aim of this review is to define the role of peripheral blood stem cell transplantation for the treatment of multiple myeloma. Therefore, we first review our present knowledge of this disease and then analyze the ...

PURPOSE OF REVIEW Provides an update of hematopoietic stem cell transplantation for systemic sclerosis from phase I/II studies and prospective randomized phase III trials, and introduces the concept of mesenchymal stem cells as potential therapy for autoimmune disease. RECENT FINDINGS Around 170 transplanted systemic sclerosis patients are registered in Europe. Most received autologous, perip...

Failure of corneal endothelium cell monolayer is the main cause leading to transplantation. Autologous cell-based therapies are required reconstruct in vitro monolayer. Several strategies have been proposed using embryonic stem cells and induced pluripotent cells, although their use has ethical issues as well limited clinical applications. For this purpose, we propose dental pulp isolated from ...

In recent years, adult stem cells isolated from postnatal tissues have aroused tremendous interest as to their potential applications in human regenerative medicine [1]. The overwhelming majority of studies in animal models and phase I human clinical trials have focused on the transplantation of relatively uncommitted or undifferentiated adult stem cells. This has disadvantages that could reduc...

PURPOSE To determine if temporarily blocking sex steroids prior to stem cell transplantation can increase thymus function and thus enhance the rate of T cell regeneration. EXPERIMENTAL DESIGN This was a pilot study of luteinizing hormone-releasing hormone agonist (LHRH-A) goserelin given 3 weeks prior to allogeneic or autologous hemopoietic stem cell transplantation and administered up to 3 m...